vs
美国国际集团（AII）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
美国国际集团的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.9倍（$68.1M vs $35.5M），美国国际集团净利率更高（30.7% vs -304.2%，领先334.9%），美国国际集团自由现金流更多（$133.2M vs $-47.3M）
美国国际集团（AIG）是一家美国跨国金融保险集团，业务遍及全球80多个国家和地区，截至2023年共有雇员25200人。集团核心业务分为三大板块：一般保险、人寿与退休服务，另设有一家独立的科技赋能子公司。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
AII vs RXRX — 直观对比
营收规模更大
AII
是对方的1.9倍
$35.5M
净利率更高
AII
高出334.9%
-304.2%
自由现金流更多
AII
多$180.5M
$-47.3M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $68.1M | $35.5M |
| 净利润 | $20.9M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 43.0% | -304.8% |
| 净利率 | 30.7% | -304.2% |
| 营收同比 | — | 681.7% |
| 净利润同比 | — | 39.6% |
| 每股收益（稀释后） | $0.58 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AIIRXRX
| Q4 25 | $68.1M | $35.5M | ||
| Q3 25 | $62.0M | $5.2M | ||
| Q2 25 | $74.5M | $19.2M | ||
| Q1 25 | $71.9M | $14.7M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | — | $26.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $13.8M |
净利润AIIRXRX
| Q4 25 | $20.9M | $-108.1M | ||
| Q3 25 | $13.2M | $-162.3M | ||
| Q2 25 | $27.5M | $-171.9M | ||
| Q1 25 | $38.1M | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | — | $-95.8M | ||
| Q2 24 | — | $-97.5M | ||
| Q1 24 | — | $-91.4M |
毛利率AIIRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率AIIRXRX
| Q4 25 | 43.0% | -304.8% | ||
| Q3 25 | 30.3% | -3327.6% | ||
| Q2 25 | 32.3% | -916.8% | ||
| Q1 25 | 59.7% | -1297.9% | ||
| Q4 24 | — | -4042.4% | ||
| Q3 24 | — | -377.1% | ||
| Q2 24 | — | -697.4% | ||
| Q1 24 | — | -698.4% |
净利率AIIRXRX
| Q4 25 | 30.7% | -304.2% | ||
| Q3 25 | 21.2% | -3135.3% | ||
| Q2 25 | 36.9% | -894.2% | ||
| Q1 25 | 53.0% | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | — | -367.5% | ||
| Q2 24 | — | -676.6% | ||
| Q1 24 | — | -662.4% |
每股收益（稀释后）AIIRXRX
| Q4 25 | $0.58 | $-0.17 | ||
| Q3 25 | $0.67 | $-0.36 | ||
| Q2 25 | $1.62 | $-0.41 | ||
| Q1 25 | $2.78 | $-0.50 | ||
| Q4 24 | — | $-0.56 | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | — | $-0.40 | ||
| Q1 24 | — | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $222.0M | $743.3M |
| 总债务越低越好 | $618.0K | $9.6M |
| 股东权益账面价值 | $337.0M | $1.1B |
| 总资产 | $1.2B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.00× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资AIIRXRX
| Q4 25 | $222.0M | $743.3M | ||
| Q3 25 | $171.9M | $659.8M | ||
| Q2 25 | $259.6M | $525.1M | ||
| Q1 25 | $236.4M | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
总债务AIIRXRX
| Q4 25 | $618.0K | $9.6M | ||
| Q3 25 | $721.0K | $11.9M | ||
| Q2 25 | $824.0K | $14.2M | ||
| Q1 25 | $926.0K | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益AIIRXRX
| Q4 25 | $337.0M | $1.1B | ||
| Q3 25 | $315.9M | $1.0B | ||
| Q2 25 | $301.9M | $919.1M | ||
| Q1 25 | $186.1M | $933.9M | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $524.6M | ||
| Q2 24 | — | $584.4M | ||
| Q1 24 | — | $401.2M |
总资产AIIRXRX
| Q4 25 | $1.2B | $1.5B | ||
| Q3 25 | $1.4B | $1.4B | ||
| Q2 25 | $1.6B | $1.3B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | — | $726.5M | ||
| Q2 24 | — | $775.9M | ||
| Q1 24 | — | $557.8M |
负债/权益比AIIRXRX
| Q4 25 | 0.00× | 0.01× | ||
| Q3 25 | 0.00× | 0.01× | ||
| Q2 25 | 0.00× | 0.02× | ||
| Q1 25 | 0.00× | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $138.2M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $133.2M | $-47.3M |
| 自由现金流率自由现金流/营收 | 195.6% | -133.1% |
| 资本支出强度资本支出/营收 | 7.4% | 3.5% |
| 现金转化率经营现金流/净利润 | 6.62× | — |
| 过去12个月自由现金流最近4个季度 | $216.1M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流AIIRXRX
| Q4 25 | $138.2M | $-46.1M | ||
| Q3 25 | $-7.5M | $-117.4M | ||
| Q2 25 | $27.4M | $-76.4M | ||
| Q1 25 | $68.1M | $-132.0M | ||
| Q4 24 | — | $-115.4M | ||
| Q3 24 | — | $-59.2M | ||
| Q2 24 | — | $-82.2M | ||
| Q1 24 | — | $-102.3M |
自由现金流AIIRXRX
| Q4 25 | $133.2M | $-47.3M | ||
| Q3 25 | $-11.9M | $-117.6M | ||
| Q2 25 | $26.9M | $-79.6M | ||
| Q1 25 | $68.0M | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率AIIRXRX
| Q4 25 | 195.6% | -133.1% | ||
| Q3 25 | -19.2% | -2272.5% | ||
| Q2 25 | 36.1% | -413.9% | ||
| Q1 25 | 94.6% | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度AIIRXRX
| Q4 25 | 7.4% | 3.5% | ||
| Q3 25 | 7.2% | 4.7% | ||
| Q2 25 | 0.6% | 16.4% | ||
| Q1 25 | 0.2% | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率AIIRXRX
| Q4 25 | 6.62× | — | ||
| Q3 25 | -0.57× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.79× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
